Market cap
$491 Mln
Recently Viewed
Clear AllMarket cap
$491 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
2.7
Div. Yield
0 %
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
$-93 Mln
ROE
-0.4 %
ROCE
-- %
Industry P/E
--
EV/EBITDA
-4
Debt to Equity
0
Book Value
$--
EPS
$-2.6
Face value
--
Shares outstanding
36,946,200
CFO
$--
EBITDA
$--
Net Profit
$--
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Akouos Inc (AKUS)
| 56.4 | -0.2 | 326.0 | 62.7 | -- | -- | -- |
|
BSE Sensex*
| -8.7 | 5.4 | -7.7 | -4.0 | 8.1 | 9.7 | 11.8 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2021
|
|---|---|
|
Akouos Inc (AKUS)
| -57.1 |
|
S&P Small-Cap 600
| 25.3 |
|
BSE Sensex
| 22.0 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Akouos Inc (AKUS)
|
13.3 | 491.0 | 0.0 | -92.6 | -- | -47.5 | -- | 2.7 |
| 0.4 | 26.6 | 0.3 | -70.2 | -21,080.9 | -217.2 | -- | 1.5 |
Akouos, Inc., a precision genetic medicine company, developing gene therapies to restore, improve, and preserve physiologic hearing for individuals. The company's precision genetic medicine platform incorporates a proprietary adeno-associated viral... vector library and a novel delivery approach. Its lead product candidate is AK-OTOF, a gene therapy for the treatment of hearing loss due to mutations in the OTOF gene. The company is also developing AK-CLRN1 for the auditory manifestations of Usher syndrome 3A, or USH3A; and AK-antiVEGF for vestibular schwannoma. In addition, its precision genetic medicine platform addresses hearing loss related to genes needed for supporting cell function. The company was incorporated in 2016 and is based in Boston, Massachusetts. Read more
Co- Founder, Pres, CEO & Director
Dr. Emmanuel Simons M.B.A., Ph.D.
Co- Founder, Pres, CEO & Director
Dr. Emmanuel Simons M.B.A., Ph.D.
Headquarters
Boston, MA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Akouos Inc (AKUS) is $13.29 (NASDAQ) as of 09-Dec-2022 09:30 EDT. Akouos Inc (AKUS) has given a return of 62.67% in the last 1 years.
Since, TTM earnings of Akouos Inc (AKUS) is negative, P/E ratio is not available.
The P/B ratio of Akouos Inc (AKUS) is 2.72 times as on 09-Dec-2022, a 47 discount to its peers’ median range of 5.09 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2021
|
-3.33
|
1.24
|
|
2020
|
-7.34
|
1.15
|
|
2019
|
--
|
--
|
|
2018
|
--
|
--
|
|
2021
|
-3.33
|
1.24
|
The 52-week high and low of Akouos Inc (AKUS) are Rs -- and Rs -- as of 04-May-2026.
Akouos Inc (AKUS) has a market capitalisation of $ 491 Mln as on 09-Dec-2022. As per SEBI classification, it is a Small Cap company.
Before investing in Akouos Inc (AKUS), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.